Wednesday, November 20, 2019
Print Current Session:
|
|
Wednesday
SESSION 24:
PROGRESS IN STENT BASED TREATMENTS, ATHERECTOMY AND LITHOPLASTY (LITHOTRIPSY) FOR LOWER EXTREMITY OCCLUSIVE LESIONS
Location: Grand Ballroom East, 3rd Floor
Moderators:Patrick J. Geraghty, MD / Kenneth Rosenfield, MD |
|
SESSION 24 SCHEDULE | |
7:52 AM - 7:57 AM | DCBs Versus DESs: Advantages And Disadvantages Of Each: Why DCBs Should Be First Line Therapy For Most Lesions In Most Patients |
Presenter(s):Thomas Zeller, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
7:58 AM - 8:03 AM | For Fempop Lesions, Zilver PTX DESs Are Durable Effective Treatment: 5-Year Results Show It Even In Adverse Circumstances: New Findings From The Zilver PTX RCT |
Presenter(s):Michael D. Dake, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:04 AM - 8:09 AM | Which Patients With Fempop Occlusive Lesions Are Not Candidates For DCB Treatment: How Should They Be Treated |
Presenter(s):Fabrizio Fanelli, MD, EBIR Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:10 AM - 8:15 AM | New Findings From The IMPERIAL RCT Comparing Zilver PTX DESs With Eluvia DESs For Fempop Lesions: Do Differences In Technology And Results In High Risk Subgroups Suggest That Eluvia Is A Better Stent |
Presenter(s):William A. Gray, MD / Stefan Mueller-Huelsbeck, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:16 AM - 8:21 AM | Not Sure That IMPERIAL RCT To Date Shows Differences That Are Important: Zilver PTX Is Still A Good DES With Favorable Longer-Term Results And Both Stents Produced Equal Improvement In Symptoms |
Presenter(s):Gary M. Ansel, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:22 AM - 8:27 AM | Another View On When To Use Which Stent For Fempop Lesions: Supera, Zilver PTX, Eluvia Or Others |
Presenter(s):Iris Baumgartner, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:28 AM - 8:33 AM | Eluvia (Boston Scientific) Is The Only Polymer Based Paclitaxel DES Technology, And It Is Now Being Studied For BTK Lesions In The SAVAL RCT |
Presenter(s):Patrick J. Geraghty, MD / Jihad A. Mustapha, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:34 AM - 8:39 AM | Bioresorbable Everolimus DESs For Treating BTK Lesions: The Results With The Absorb Stent (Abbott) Were Favorable For 5 Years: What Does The Future Hold For Such Stents |
Presenter(s):Steven Kum, MD / Ramon L. Varcoe, MBBS, MS, FRACS, PhD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:40 AM - 8:45 AM | Current Status And Improvements In Atherectomy Devices: Which One Or Ones Are Best And Why: For Stand-Alone Treatment Or For Vessel Preparation For Other Treatments |
Presenter(s):Lawrence A. Garcia, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:46 AM - 8:51 AM | Which Atherectomy Device Is Best And Why; A European Perspective And Shockwave Based Technology With A Jack-Hammer Effect To Facilitate CTO Wire Crossing (From Soundbite Medical Solutions); How It Works |
Presenter(s):Marianne Brodmann, MD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:52 AM - 8:57 AM | Update On Intravascular Lithotripsy (Lithoplasty) To Treat Calcified Occlusive Lesions: When Is It Worthwhile And When Not: From The DISRUPT PAD Trials And The REAL World Registry |
Presenter(s):Andrew Holden, MBChB Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
8:58 AM - 9:02 AM | Late Breaking 5-Year Results Of Bioresorbable DES (Abbott) For BTK Lesions: Future Implications |
Presenter(s):Brian G. DeRubertis, MD / Ramon L. Varcoe, MBBS, MS, FRACS, PhD Location: Grand Ballroom East, 3rd Floor |
|
View Slides in PDF | |
9:02 AM - 9:10 AM | Panel Discussion And Break Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 24 | |
previous | next |